Platelet Function Analyzer-200 P2Y Results Are Predictive of the Risk of Major Adverse Cardiac Events in Korean Patients Receiving Clopidogrel Therapy Following Acute Coronary Syndrome
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Clopidogrel is one of the most commonly used anti-platelet agents in cardiovascular diseases. We analyzed the relationship between the platelet function analyzer (PFA)-200 P2Y (INNOVANCE PFA-200 System, Siemens Healthcare, Germany) results and occurrence of major adverse cardiac events (MACEs) in Korean patients with recent-onset acute coronary syndrome (ACS) taking clopidogrel. Methods: Between August 2013 and June 2016, we prospectively enrolled 106 patients with recent-onset ACS who had been treated with clopidogrel. We obtained blood samples and measured closure time (CT) using the PFA-200 P2Y test. Patients were divided into two groups on the basis of a CT cut-off value of 106 seconds. We compared patient characteristics and various MACEs that occurred during the follow-up period. Results: The CTs for 78 patients exceeded the cut-off value. At the time of these analyses, 11 patients had been diagnosed with MACEs. In the time-to-event analysis, there was a difference between the two groups (P<0.001). After adjusting other variables associated with MACE occurrence, CT value was the strongest predictor of MACEs, with a 7.30-fold occurrence risk (P=0.002). Conclusions: We found a strong relationship between CT and MACE risk in Korean patients with recent-onset ACS taking clopidogrel. Accordingly, PFA-200 P2Y results could be used as a predictive marker for MACE risk in such patients.
Abstract
Background: Clopidogrel is one of the most commonly used anti-platelet agents in cardiovascular diseases. We analyzed the relationship between the platelet function analyzer (PFA)-200 P2Y (INNOVANCE PFA-200 System, Siemens Healthcare, Germany) results and occurrence of major adverse cardiac events (MACEs) in Korean patients with recent-onset acute coronary syndrome (ACS) taking clopidogrel. Methods: Between August 2013 and June 2016, we prospectively enrolled 106 patients with recent-onset ACS who had been treated with clopidogrel. We obtained blood samples and measured closure time (CT) using the PFA-200 P2Y test. Patients were divided into two groups on the basis of a CT cut-off value of 106 seconds. We compared patient characteristics and various MACEs that occurred during the follow-up period. Results: The CTs for 78 patients exceeded the cut-off value. At the time of these analyses, 11 patients had been diagnosed with MACEs. In the time-to-event analysis, there was a difference between the two groups (P<0.001). After adjusting other variables associated with MACE occurrence, CT value was the strongest predictor of MACEs, with a 7.30-fold occurrence risk (P=0.002). Conclusions: We found a strong relationship between CT and MACE risk in Korean patients with recent-onset ACS taking clopidogrel. Accordingly, PFA-200 P2Y results could be used as a predictive marker for MACE risk in such patients.
참고문헌 (35)
- "Health insurance review & assessment service, healthcare bigdata hub"[URL]
- Stoll G, "Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment", Blood, 112, pp.3555~3562 (2008)[DOI]
- Hollopeter G, "Identification of the platelet ADP receptor targeted by antithrombotic drugs", Nature, 409, pp.202~207 (2001)[DOI]
- Anderson JL, "2011 ACCF", AHA focused update incorporated into the ACC, non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation, pp.American Heart Association Task Force on Practice Guidelines, Circulation[DOI]
- European Association for Percutaneous Cardiovascular Interventions (EAPCI), "Guidelines on myocardial revascularization: Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)", Eur Heart J, 31, pp.2501~2555 (2010)[DOI]
- Gurbel PA, "Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity", Circulation, 107, pp.2908~2913 (2003)[DOI]
- Jaremo P, "Individual variations of platelet inhibition after loading doses of clopidogrel", J Intern Med, 252, pp.233~238 (2002)[DOI]
- Price MJ, "Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers", Am J Cardiol, 98, pp.681~684 (2006)[DOI]
- Angiolillo DJ, "Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives", J Am Coll Cardiol, 49, pp.1505~1516 (2007)[DOI]
- Matetzky S, "Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction", Circulation, 109, pp.3171~3175 (2004)[DOI]
- Renda G, "Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance", Haematologica, 95, pp.2095~2101 (2010)[DOI]
- Lordkipanidze M, "A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease", Eur Heart J, 28, pp.1702~1708 (2007)[DOI]
- Koessler J, "The new INNOVANCE PFA P2Y cartridge is sensitive to the detection of the P2Y12 receptor inhibition", Platelets, 22, pp.20~27 (2011)
- Choi JL, "Platelet function tests: a review of progresses in clinical application", Biomed Res Int, 2014, pp.456569~ (2014)
- Tsantes A, "Evaluation of the role of the new INNOVANCE PFA P2Y test cartridge in detection of clopidogrel resistance", Platelets, 23, pp.481~489 (2012)[DOI]
- Angiolillo DJ, "Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment", Diabetes, 54, pp.2430~2435 (2005)[DOI]
- Soffer D, "Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina?", Catheter Cardiovasc Interv, 59, pp.21~25 (2003)[DOI]
- Angiolillo DJ, "Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?", J Invasive Cardiol, 16, pp.169~174 (2004)
- Angiolillo DJ, "Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment", J Am Coll Cardiol, 48, pp.298~304 (2006)[DOI]
- Taubert D, "Pharmacokinetics of clopidogrel after administration of a high loading dose", Thromb Haemost, 92, pp.311~316 (2004)
- Lau WC, "Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction", Circulation, 107, pp.32~37 (2003)[DOI]
- Neubauer H, "Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function-a flow cytometry study", Eur Heart J, 24, pp.1744~1749 (2003)[DOI]
- Angiolillo DJ, "Clopidogrel-statin interaction: myth or reality?", J Am Coll Cardiol, 50, pp.296~298 (2007)[DOI]
- Go AS, "Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization", N Engl J Med, 351, pp.1296~1305 (2004)[DOI]
- Shlipak MG, "Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency", Circulation, 107, pp.87~92 (2003)[DOI]
- London GM, "Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality", Nephrol Dial Transplant, 18, pp.1731~1740 (2003)[DOI]
- Muntner P, "The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease", Ann Intern Med, 140, pp.9~17 (2004)[DOI]
- Kip KE, "The problem with composite end points in cardiovascular studies", J Am Coll Cardiol, 51, pp.701~707 (2008)[DOI]
- Angiolillo DJ, "Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel", Arterioscler Thromb Vasc Biol, 26, pp.1895~1900 (2006)[DOI]
- Beitelshees AL, "Clopidogrel pharmacogenetics: promising steps towards patient care", Arterioscler Thromb Vasc Biol, 26, pp.1681~1683 (2006)[DOI]
- Hulot JS, "Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects", Blood, 108, pp.2244~2247 (2006)[DOI]
- Shuhua Li, "Correlation Between the CYP2C19 Phenotype Status and the Results of Three Different Platelet Function Tests in Cardiovascular Disease Patients Receiving Antiplatelet Therapy: An Emphasis on Newly Introduced Platelet Function Analyzer-200 P2Y Test", Annals of Laboratory Medicine, 36(1), pp.42~48 (2016), 대한진단검사의학회
- Trenk D, "Cytochrome P450 2C19 681G > A polymorphism and high on clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents", J Am Coll Cardiol, 51, pp.1925~1934 (2008)[DOI]
- Collet JP, "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study", Lancet, 373, pp.309~317 (2009)[DOI]
- Simon T, "Genetic determinants of response to clopidogrel and cardiovascular events", N Engl J Med, 360, pp.363~375 (2009)[DOI]